Nicotinic Agonist Effects on BMI and Neuronal Response in Overweight/Obese Adults
烟碱激动剂对超重/肥胖成人的 BMI 和神经元反应的影响
基本信息
- 批准号:9767131
- 负责人:
- 金额:$ 35.42万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2015
- 资助国家:美国
- 起止时间:2015-08-06 至 2021-06-30
- 项目状态:已结题
- 来源:
- 关键词:AddressAffinityAgonistAnimal ModelAnimalsAnteriorBehaviorBehavioralBehavioral MechanismsBody WeightBody Weight ChangesBody Weight decreasedBody fatBrainBrain regionCardiovascular DiseasesCholinergic ReceptorsCognitionCoronary heart diseaseCuesDesire for foodDiabetes MellitusDiseaseDopamineEatingEnergy IntakeEnergy MetabolismFatty acid glycerol estersFeeding PatternsFoodFood Intake RegulationFunctional disorderGeneral PopulationGoalsHealthHumanHungerHypertensionHypothalamic structureIndividualInsula of ReilKnowledgeMalignant NeoplasmsMeasuresMetabolicMusculoskeletal DiseasesNeuroanatomyNeurobiologyNeuronsNicotineNicotinic AgonistsNicotinic ReceptorsObesityOutcomeOverweightPathway interactionsPatientsPharmaceutical PreparationsPhysiologicalPlacebosPlayProcessPublic HealthQuality of lifeResearchResearch DesignRestRewardsRisk FactorsRoleSatiationSchizophreniaStrategic PlanningStudy modelsThinnessUnited States National Institutes of HealthVentral StriatumVisualWeightWeight GainWeight maintenance regimenadult obesityanabaseinebehavior measurementcholinergicfeedingimprovedmortality riskmouse modelnerve supplynovelnovel strategiespublic health relevancereceptor expressionresponsetreatment strategyweight maintenance
项目摘要
DESCRIPTION (provided by applicant): Obesity is a profound public health issue, associated with increased mortality and risk for multiple diseases, including cardiovascular disease, diabetes, musculoskeletal disorders, and cancer. Weight loss in obese individuals reduces many of these risk factors, but weight loss and maintenance can be extremely difficult. Clearly, developing new approaches to treat obesity is an important goal, and is a key component of the Strategic Plan for NIH Obesity Research. A possible novel mechanism for treating obesity is activation of the a7 nicotinic cholinergic receptor. Nicotine's association with reduced body weight, and its ability to suppress appetite, increase energy expenditure and alter feeding patterns is well established. Recent evidence suggests that the a7 nicotinic receptor may play a particularly prominent role in these effects. Recent findings by our group separately examining the neuronal mechanisms of food intake behavior in non-mentally ill subjects and the neurobiology of nicotinic cholinergic dysfunction in schizophrenia unexpectedly have converged, showing that some of the same brain intrinsic network components that are overactive in obese individuals are down-modulated by an a7 nicotinic receptor agonist in patients. Given these effects, we recently conducted an initial study of the effect of the a7 nicotinic receptor partial agonist 3-2,4 dimethoxybenzylidene anabaseine (DMXB-A) on weight, appetite and neuronal measures of the response to visual food cues in patients. These measures were an add- on outcome of a study designed to examine drug effects on cognition. Compared to placebo, DMXB-A was associated with significant weight loss and a reduction in hunger and appetite. Neuronally, DMXB-A was associated with alterations in the same brain regions we previously found to be involved in the response to food intake in lean compared to obese-prone individuals. We also found that the DMXB-A-associated change in insula response to food cues was related to weight change. Considering these preliminary results, and emerging evidence from animal studies, activation of a7 nicotinic receptors may be a novel mechanism to alter neuronal processes of food intake behavior and improve weight management in overweight/obese individuals in the general population. The overall goal of this application is to understand the effects of an a7 nicotinic receptor partial agonist on neuronal, physiological, and behavioral mechanisms of obesity in the general population. It is hoped that results of this study will inform
our knowledge of nicotinic cholinergic involvement in obesity, potentially leading to novel treatment strategies to address a critical problem that negatively impacts health and quality of life.
描述(由申请人提供):肥胖是一个深刻的公共卫生问题,与多种疾病的死亡率和风险增加相关,包括心血管疾病、糖尿病、肌肉骨骼疾病和癌症,肥胖个体的体重减轻可以减少许多这些风险因素。显然,开发治疗肥胖的新方法是一个重要目标,也是 NIH 肥胖研究战略计划的关键组成部分。治疗肥胖的一种可能的新机制是激活 a7。烟碱胆碱能受体。最近的研究表明,烟碱受体可能在这些作用中发挥着特别重要的作用。我们的小组分别研究了非精神病受试者食物摄入行为的神经元机制和精神分裂症烟碱胆碱能功能障碍的神经生物学,出乎意料地出现了收敛,表明一些肥胖个体中过度活跃的相同大脑内在网络成分会被患者中的 a7 烟碱受体激动剂下调。鉴于这些影响,我们最近对 a7 烟碱受体部分激动剂 3-2,4 二甲氧基亚苄基的作用进行了初步研究。 anabaseine (DMXB-A) 对患者体重、食欲和对视觉食物线索反应的神经测量的影响这些测量是一项旨在检查药物作用的研究的附加结果。与安慰剂相比,DMXB-A 与显着的体重减轻以及饥饿感和食欲的降低有关。在神经元上,DMXB-A 与我们之前发现的参与食物摄入反应的相同大脑区域的变化有关。与肥胖人群相比,我们还发现,DMXB-A 相关的岛叶对食物信号的反应变化与体重变化有关,并且考虑到这些初步结果以及来自动物研究的新证据,a7 烟碱的激活。受体可能是改变神经元食物摄入行为过程并改善普通人群超重/肥胖个体体重管理的新机制。本申请的总体目标是了解α7烟碱受体部分激动剂对神经元、生理学的影响。 ,以及一般人群肥胖的行为机制,希望这项研究的结果能够提供信息。
我们对烟碱胆碱能参与肥胖的了解,可能会导致新的治疗策略来解决对健康和生活质量产生负面影响的关键问题。
项目成果
期刊论文数量(4)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Targeting Functional Biomarkers in Schizophrenia with Neuroimaging.
- DOI:10.2174/1381612822666160127113912
- 发表时间:2016
- 期刊:
- 影响因子:3.1
- 作者:Wylie KP;Smucny J;Legget KT;Tregellas JR
- 通讯作者:Tregellas JR
Alpha7 Nicotinic Receptors as Therapeutic Targets in Schizophrenia.
- DOI:10.1093/ntr/nty034
- 发表时间:2018-08
- 期刊:
- 影响因子:0
- 作者:J. Tregellas;Korey P. Wylie
- 通讯作者:J. Tregellas;Korey P. Wylie
Effects of Dietary Protein and Fiber at Breakfast on Appetite, ad Libitum Energy Intake at Lunch, and Neural Responses to Visual Food Stimuli in Overweight Adults.
- DOI:10.3390/nu8010021
- 发表时间:2016-01-05
- 期刊:
- 影响因子:5.9
- 作者:Sayer RD;Amankwaah AF;Tamer GG Jr;Chen N;Wright AJ;Tregellas JR;Cornier MA;Kareken DA;Talavage TM;McCrory MA;Campbell WW
- 通讯作者:Campbell WW
Reproducibility assessment of brain responses to visual food stimuli in adults with overweight and obesity.
- DOI:10.1002/oby.21603
- 发表时间:2016-10
- 期刊:
- 影响因子:6.9
- 作者:Sayer, R. Drew;Tamer, Gregory G., Jr.;Chen, Ningning;Tregellas, Jason R.;Cornier, Marc-Andre;Kareken, David A.;Talavage, Thomas M.;McCrory, Megan A.;Campbell, Wayne W.
- 通讯作者:Campbell, Wayne W.
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
JASON R TREGELLAS其他文献
JASON R TREGELLAS的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('JASON R TREGELLAS', 18)}}的其他基金
Neuronal and behavioral effects of an implicit priming approach to improve eating behaviors in obesity
隐式启动方法改善肥胖饮食行为的神经元和行为效应
- 批准号:
10551293 - 财政年份:2021
- 资助金额:
$ 35.42万 - 项目类别:
Neuronal and behavioral effects of an implicit priming approach to improve eating behaviors in obesity
隐式启动方法改善肥胖饮食行为的神经元和行为效应
- 批准号:
10209808 - 财政年份:2021
- 资助金额:
$ 35.42万 - 项目类别:
Neuronal and behavioral effects of an implicit priming approach to improve eating behaviors in obesity
隐式启动方法改善肥胖饮食行为的神经元和行为效应
- 批准号:
10388376 - 财政年份:2021
- 资助金额:
$ 35.42万 - 项目类别:
Reducing Hippocampal Hyperactivity and Improving Cognition in Schizophrenia
减少海马过度活跃并改善精神分裂症患者的认知
- 批准号:
10038801 - 财政年份:2017
- 资助金额:
$ 35.42万 - 项目类别:
Reducing Hippocampal Hyperactivity and Improving Cognition in Schizophrenia
减少海马过度活跃并改善精神分裂症患者的认知
- 批准号:
10295165 - 财政年份:2017
- 资助金额:
$ 35.42万 - 项目类别:
Reducing Hippocampal Hyperactivity and Improving Cognition in Schizophrenia
减少海马过度活跃并改善精神分裂症患者的认知
- 批准号:
10671447 - 财政年份:2017
- 资助金额:
$ 35.42万 - 项目类别:
Nicotinic Agonist Effects on BMI and Neuronal Response in Overweight/Obese Adults
烟碱激动剂对超重/肥胖成人的 BMI 和神经元反应的影响
- 批准号:
8960808 - 财政年份:2015
- 资助金额:
$ 35.42万 - 项目类别:
Nicotinic Agonist Effects on BMI and Neuronal Response in Overweight/Obese Adults
烟碱激动剂对超重/肥胖成人的 BMI 和神经元反应的影响
- 批准号:
9307811 - 财政年份:2015
- 资助金额:
$ 35.42万 - 项目类别:
相似国自然基金
抗原非特异性B细胞进入生发中心并实现亲和力成熟的潜力与调控机制
- 批准号:32370941
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
面向免疫疗法标志物识别的基于多特征融合的肽与MHC亲和力预测研究
- 批准号:62302277
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
基于计算生物学技术小分子农兽药残留物驼源单域抗体虚拟筛选与亲和力成熟 -以内蒙古阿拉善双峰驼为例
- 批准号:32360190
- 批准年份:2023
- 资助金额:34 万元
- 项目类别:地区科学基金项目
基于胞内蛋白亲和力标记策略进行新型抗类风湿性关节炎的选择性OGG1小分子抑制剂的发现
- 批准号:82304698
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
面向多场景应用的药物-靶标结合亲和力预测研究
- 批准号:62371403
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
相似海外基金
A Novel Approach to Target Neutrophilic Airway Inflammation and Airway Hyperresponsiveness in Therapy-Resistant (Refractory) Asthma.
一种针对难治性哮喘中性粒细胞性气道炎症和气道高反应性的新方法。
- 批准号:
10659658 - 财政年份:2023
- 资助金额:
$ 35.42万 - 项目类别:
Development of High-Affinity and Selective Ligands as a Pharmacological Tool for the Dopamine D4 Receptor (D4R) Subtype Variants
开发高亲和力和选择性配体作为多巴胺 D4 受体 (D4R) 亚型变体的药理学工具
- 批准号:
10682794 - 财政年份:2023
- 资助金额:
$ 35.42万 - 项目类别:
PPARdelta receptors and alcohol use phenotypes
PPARδ 受体和饮酒表型
- 批准号:
10682348 - 财政年份:2023
- 资助金额:
$ 35.42万 - 项目类别:
Structural and Allosteric Mechanisms of mGluR Activation
mGluR 激活的结构和变构机制
- 批准号:
10679316 - 财政年份:2023
- 资助金额:
$ 35.42万 - 项目类别: